S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 09 Apr 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Apr 2021.